Figure 4 | Cell Death & Disease

Figure 4

From: Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152

Figure 4

Effect of SMAC mimetic GDC-0152 on survival and tumor growth of mice bearing intracranial tumors. (a) A total of 100 000 U87MG-iRFP cells were injected into the corpus callosum of athymic nude mice. At 1 week after injection, mice were treated either with DMSO (n=7) or 10 mg/kg (n=7) or 20 mg/kg (n=7) of GDC-0152. OS curves of mice were estimated by the Kaplan–Meier method. GDC-0152 increased mice survival in a dose-dependent manner. (b) Images of representative U87MG-iRFP tumors according to treatments are shown. For each group of mice ((A) DMSO group (group A); (B) mice treated with 10 mg/kg GDC-0152 (group B) and (C) mice treated with 20 mg/kg GDC-0152 (group C)), graphs represent the normalized growth curve for each animal that developed a tumor. In addition, we observed that 7/7 mice developed a tumor in group A, 5/7 in group B and 3/7 in group C. In this group one mouse developed a tumor 2 weeks after the end of treatment (blue line). The mouse representative of the DMSO group corresponds to the black line; the mouse representative of the 10 mg/kg GDC-0152 corresponds to the blue line; the mouse representative of the 20 mg/kg GDC-0152 corresponds to the green line. W, weeks. GDC-0152 treatment slowed down tumor growth

Back to article page